Patents Assigned to GENMAG A/S
  • Modulation of complement-dependent cytotoxicity through modifications of the C-terminus of antibody heavy chains
    Patent number: 10323081
    Abstract: Provided are antibody variants having decreased or increased ability to mediate complement-dependent cytotoxicity (CDC) due to the presence or absence of C-terminal lysines of their heavy chains. Also provided are methods of generating such antibodies, as well as nucleotide constructs and host cells suitable for the production of such antibodies.
    Type: Grant
    Filed: July 6, 2012
    Date of Patent: June 18, 2019
    Assignee: GENMAG A/S
    Inventors: Paul Parren, Patrick Van Berkel, Ewald T. J. Van Den Bremer